Safety and Efficacy of GENOSS® DCB With a Shellac Plus Vitamin E Excipient in Patients With De Novo Lesion

Inclusion Criteria: * Adults over the age of 19 * Patients with new lesions with coronary small vascular disease (vascular diameter \<3.0 mm) underwent a GENOSS® DCB procedure through percutaneous coronary intervention * Subjects who agreed to the clinical research plan and the clinical follow-up plan, voluntarily decided to participate in this clinical study, and agreed in writing to the consent of the study subjects Exclusion Criteria: * Subjects who plan to become pregnant during the period of this study as women of the gestational age * Subjects whose remaining life expectancy is expected to be less than one year * Subjects who visited the hospital due to psychogenic shock at the time of visiting the hospital and are predicted to have a low chance of survival based on medical judgment * If it falls under any of the following items after prior dilation of the target lesion; * Stent procedures are required due to vascular detachment that limits blood flow * If the residual stenosis is \>30% * If the TIMI flow is \<3 * Subjects participating in a randomized study of medical devices * If the researcher determines that it is not appropriate for this clinical study or may increase the risk associated with participation in the study